Cipla Limited announced strong financial performance for the financial year ended March 31, 2026, with record annual revenue supported by robust growth across India, North America, Africa, and emerging markets. The company reported its highest-ever annual revenue of ₹28,163 crore for FY26, reflecting continued momentum across key therapeutic categories and international operations despite ongoing geopolitical and market-related challenges in certain regions.
Cipla stated that its India business crossed the ₹12,500 crore annual revenue milestone, driven by sustained growth across branded prescription medicines, trade generics, and consumer healthcare products. The company’s One-India business recorded robust quarterly growth of 15% year-on-year, with all three business segments delivering double-digit expansion during the quarter ended March 2026.
Key chronic therapies including respiratory, cardiac, anti-diabetes, and urology maintained strong momentum throughout the year. The company noted that chronic therapies now account for 60.2% of its branded prescription business mix.
Among flagship brands, Foracort crossed the ₹1,000 crore revenue milestone, while cardiac brand Dytor emerged as a ₹650 crore-plus franchise with 25% year-on-year growth in the Indian pharmaceutical market. Cipla’s trade generics business continued to deliver strong double-digit growth supported by product launches, execution across core therapies, and digital interventions aimed at improving market reach.
The consumer health business also maintained momentum with brands such as Nicotex, Omnigel, and Cipladine retaining leadership positions within their respective categories. In North America, Cipla recorded annual revenue of USD 780 million, supported by steady demand for differentiated products and a stable base business. During the year, the company advanced several important product launches including Liraglutide, Nintedanib, and Dapagliflozin.
The company also received regulatory approval for the first AB-rated generic Ventolin product manufactured at its U.S. facility, marking a significant milestone in respiratory drug manufacturing. Cipla’s One Africa business recorded annual growth of 7% year-on-year in dollar terms, supported by strong performance across private markets, expansion of over-the-counter products, and new product introductions.
Emerging Markets and Europe crossed the USD 400 million annual revenue threshold during the year, driven by focused market strategies and expansion across both direct-to-market and business-to-business segments. Research and development investments during the quarter stood at ₹509 crore, representing 7.8% of quarterly sales. The company stated that investments were directed toward product development, regulatory filings, and future pipeline expansion.
Cipla also maintained a strong balance sheet with a net cash position of ₹10,526 crore as of March 31, 2026. On the regulatory front, the company confirmed successful completion of U.S. FDA inspections at its manufacturing facilities in Bengaluru, Navi Mumbai, and Goa, with all facilities receiving either Voluntary Action Indicated or No Action Indicated classifications.
Commenting on the performance, Achin Gupta, Managing Director and Global CEO of Cipla, stated that the company continued to strengthen its position across key markets while building future growth platforms through investments in brands, pipeline development, and regulatory compliance.
The Board of Directors recommended a final dividend of ₹13 per equity share of face value ₹2 each for FY26, subject to shareholder approval at the company’s upcoming Annual General Meeting. Cipla stated that it remains focused on sustainable growth, strengthening access to affordable healthcare, and expanding its presence across regulated and emerging pharmaceutical markets globally.
Founded in 1935, Cipla has grown into a global pharmaceutical company with a strong presence across India, South Africa, North America, and other regulated and emerging markets. With 46 manufacturing facilities worldwide, the company produces a wide range of dosage forms and serves more than 80 markets.
